Preparing for Tuberculosis Vaccine M72/AS01E Implementation
This correction relates to the global demand forecast for the potential implementation of the M72/AS01E TB vaccine
Malawi
ZAMSA-TB: Advancing epidemiological methods for surveillance of Mycobacterium tuberculosis infection
Multi-country study developing and validating clinic-based convenience sampling of Mtb immunoreactivity (IGRA) in children aged 1-5 as a sentinel measure of recent TB transmission. Outputs include geospatial identification of high-transmission neighbourhoods to target adult/adolescent vaccine delivery, and Monte Carlo simulations to size convenience-sampling surveys able to detect population-level vaccine effectiveness during roll-out.
Assessing the readiness of communities and civil society to contribute to new TB vaccine policy making and implementation
Three-part study to assess the readiness of community and civil society to contribute to TB vaccine policymaking and implementation at national, regional, and global levels, and the investments funders should make to strengthen community capacity and engagement. 1) No Vaccines Without Us: A Global Landscape Analysis of Civil Society Engagement in TB Vaccine Preparedness is based on a global survey of 125 civil society organizations active in the TB response in 42 countries. 2) Country Policy Portraits, written by local activists, illustrate how vaccine policy is made in seven countries — Bangladesh, Kazakhstan, Kenya, Malawi, Mongolia, South Africa, and Vietnam — and propose reforms to strengthen the representation of community partners in national immunization decision making. 3) TB Vaccine Access in “4D”: A Roadmap Charting Civil Society Actions for Equitable Access outlines a series of actions civil society can take to assure access to new TB vaccines along four dimensions: development, delivery, demand, and data.
New Tuberculosis vaccines for people with HIV
Mathematical modelling study assessing how different strategies for vaccinating people with and without HIV could reduce TB cases among people with HIV in high HIV/TB burden countries
The potential health and economic impact of introducing the vaccine candidate VPM1002 to prevent tuberculosis disease in low- and middle-income countries
This study estimates the potential health and economic impact of introducing the TB vaccine candidate VPM1002 in 79 low- and middle- income countries. It models routine vaccination and vaccination campaigns, estimating TB cases and deaths averted and the cost-effectiveness of different introduction scenarios. It provides evidence for decisions about the potential future introduction and scale-up of VPM1002
The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries
Estimates the potential economic impact of introducing novel TB vaccines in 105 low- and middle- income countries. It compares ifnant and adolescents/ adult vaccination scenarios and models their effects on TB- related mortality, morbidity, healthcare costs and GDP. Finding support decision making on the future development and introduciton of novel TB vaccines
Facing up to reality? What to do if M72/AS01E doses are limited
The Ph3 trial for the vaccine candidate M72/AS01E is underway, and, assuming a
positive result, could be licensed by 2030. Modelling suggested a large potential impact from
introducing M72/AS01E but assumed an unconstrained dose supply. However, at least initially, it is
likely that M72/AS01E will be supply-constrained. We estimated the effect of decisions surrounding
the allocation of constrained doses on the potential global impact of M72/AS01E
Cost and Cost Effectiveness of Novel Tuberculosis Vaccines in Low-and Middle-income Countries: A Systematic Review of Modelling Studies
This review addressed the costs and cost-effectiveness of novel tuberculosis (TB) vaccines compared to the current standard of care (BCG) in various settings and for different age groups in LMICs
Modelling to estimate the health impact of novel tuberculosis vaccines on TB burden in people living with HIV
This project will inform tuberculosis (TB) prevention efforts by estimating the health impact of novel tuberculosis vaccines on TB burden in people living with HIV (PLHIV) using a novel Mycobacterium tuberculosis transmission model. HIV confers the largest relative risk of TB, and new TB vaccines could be an important tool to prevent TB; however, modelling studies have not systematically investigated how new vaccines will affect TB burden in PLHIV. In stage 1 of this project, we aim to investigate TB vaccine impact in PLHIV where vaccine product characteristics and delivery vary by recipient HIV status. In stage 2, we aim to quantify how complex vaccine targeting strategies and incorporating additional granularity in HIV/AIDS natural history might affect vaccine impact estimates in PLHIV
Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report
A workshop to asked high TB burden country experts about what epidemiological, impact, feasibility and acceptability data they anticipated they would need to guide TB vaccine introduction.